Reviewing Cellular Dynamics International (ICEL) and Repros Therapeutics (RPRX)

Cellular Dynamics International (NASDAQ: ICEL) and Repros Therapeutics (NASDAQ:RPRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Valuation and Earnings

How to Become a New Pot Stock Millionaire

This table compares Cellular Dynamics International and Repros Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellular Dynamics International N/A N/A N/A N/A N/A
Repros Therapeutics $50,000.00 530.10 -$17.27 million N/A N/A

Cellular Dynamics International has higher earnings, but lower revenue than Repros Therapeutics.

Profitability

This table compares Cellular Dynamics International and Repros Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Dynamics International -88.12% -57.59% -38.09%
Repros Therapeutics N/A N/A -134.23%

Insider & Institutional Ownership

13.6% of Repros Therapeutics shares are owned by institutional investors. 2.5% of Repros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cellular Dynamics International and Repros Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Dynamics International 0 0 0 0 N/A
Repros Therapeutics 0 1 0 0 2.00

Repros Therapeutics has a consensus target price of $0.39, indicating a potential downside of 41.79%. Given Repros Therapeutics’ higher possible upside, analysts plainly believe Repros Therapeutics is more favorable than Cellular Dynamics International.

Summary

Repros Therapeutics beats Cellular Dynamics International on 6 of the 7 factors compared between the two stocks.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive News & Ratings for Cellular Dynamics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply